April 22nd 2024
Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Community Practice Connections™: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
6th Annual Precision Medicine Symposium: An Illustrated Tumor Board
October 18-19, 2024
Register Now!
Advances in TNBC: Communicating with Your Patients About Clinical Trial Awareness and Treatment Concerns to Improve Clinical Outcomes
View More
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
SunRISE Program Incites Optimism About the Future of High-Risk, BCG-Unresponsive NMIBC Treatment
May 24th 2023In an interview with Targeted Oncology, Siamak Daneshmand, MD, discussed TAR-200 as seen in the SunRISE-1 trial and the what is up next for the treatment landscape of high-risk BCG-unresponsive non-muscle invasive bladder cancer.
Read More
KEYNOTE-057 Results Add New Treatment Option for Certain Patients with Bladder Cancer
May 16th 2023In an interview with Targeted Oncology, Petros Grivas, MD, PhD, discusses the set up and key results from the KEYNOTE-057 trial of pembrolizumab for patients with bacillus Calmette-Guérin-unresponsive, papillary high-risk non–muscle-invasive bladder cancer.
Read More
Assessing Effectiveness and Toxicities in Emerging Therapies in Bladder Cancer
April 19th 2023At the 2023 National Comprehensive Cancer Network Annual Conference, Arlene O. Siefker-Radtke, MD, gave an assessment on where emerging targeted therapies for patients with metastatic or advanced bladder stand.
Read More
Real-World Data Supports Avelumab Use for Locally Advanced, Metastatic Urothelial Carcinoma
February 20th 2023Treatment with avelumab for locally advanced or metastatic urothelial carcinoma showed to be consistent in a real-world with what was previously seen in the phase 3 JAVELIN Bladder 100 trial.
Read More
Long-Term Survival Benefit in Muscle-Invasive Urothelial Cancer Impacted by Nivolumab
February 18th 2023Extended follow-up findings of the phase 3 CheckMate 274 study further support the use of nivolumab as a standard of care in high-risk muscle-invasive urothelial carcinoma following radical resection.
Read More
Antitumor Activity Associated With Pembrolizumab in BCG-Unresponsive Papillary NMIBC
February 18th 2023Pembrolizumab generated antitumor activity in patients with BCG-unresponsive, papillary high-risk non–muscle-invasive bladder cancer, according to cohort B of the phase 2 Keynote-057 trial.
Read More
Sustained Benefit With Sacituzumab Govitecan Following CPI in Platinum-Ineligible mUC
February 17th 2023Sacituzumab govitecan-hziy demonstrated a promising objective response rate in platinum-ineligible patients with metastatic urothelial cancer after progression on an immune checkpoint inhibitor.
Read More
BT8009 Generates Encouraging Preliminary Antitumor Activity in Urothelial Cancer
February 17th 2023The phase 1 dose-escalation portion of a phase 1/2 trial evaluating BT8009 in patients with urothelial cancer led to promising overall response and clinical benefit rates, including 1 complete response at the 5 mg/m2 dose.
Read More
A Closer Look at the Most Recent NCCN Guidelines for Bladder Cancer
January 24th 2023In an interview with Targeted Oncology, Thomas Flaig, MD, further discussed the updates to the 2022 NCCN guidelines for patients with bladder cancer and explained how the field has evolved over the past few years.
Read More
Safety and Efficacy Data from CheckMate 274 on Adjuvant Nivolumab Therapy for Patients with MIBC
January 23rd 2023Matthew Galsky, MD, explains safety and efficacy data from the CheckMate 274 trial, which led to the FDA approval of adjuvant nivolumab for patients with MIBC, and highlights important data updates from recent conferences.
Watch
Roundtable Discussion: Moon Discusses Best Path for Maintenance Care in Advanced Bladder Cancer
January 13th 2023During a Targeted Oncology case-based roundtable event, Helen Moon, MD, discussed with participants their approaches to metastatic bladder cancer and immunotherapy in the switch maintenance setting.
Read More